Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension

Oral treprostinil has been shown to improve exercise capacity and delay disease progression in patients with pulmonary arterial hypertension (PAH), but its effects on hemodynamics are not well-characterized. The FREEDOM-EV trial was a Phase III, international, placebo-controlled, double-blind, event...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Akram, White, R. James, Meyer, Gisela, Zamudio, Tomas R. Pulido, Jerjes-Sanchez, Carlos, Johnson, Dana, Grover, Rob, Broderick, Meredith, Ousmanou, Aliou, Holdstock, Louis, Michelakis, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024312/
https://www.ncbi.nlm.nih.gov/pubmed/35134631
http://dx.doi.org/10.1016/j.rmed.2022.106744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024312/
https://www.ncbi.nlm.nih.gov/pubmed/35134631
http://dx.doi.org/10.1016/j.rmed.2022.106744

Ejemplares similares